TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurotech International ( (AU:NTI) ) just unveiled an announcement.
Neurotech International Limited reported a significant financial loss for the year ended June 30, 2025, with revenues down by 23% to $2.581 million and a 100% increase in losses, amounting to $10.599 million. The decline in revenue was primarily due to a decrease in R&D Grant Income, while the substantial loss was largely attributed to high research and development expenditure, which totaled $9.941 million. The company’s net tangible assets per ordinary security also fell from 1.17 cents to 0.28 cents, indicating a challenging financial period.
More about Neurotech International
Neurotech International Limited operates in the biotechnology industry, focusing on developing and commercializing neurological solutions. The company is involved in research and development activities aimed at creating innovative products to address neurological disorders.
Average Trading Volume: 811,694
Technical Sentiment Signal: Sell
Current Market Cap: A$13.65M
Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.